


Bird Goën & Co C.V.B.A.

William Bird, MA (Cambridge), C.Eng. (1)(2)(3)(4)(5)
Ariane Bird (Goën) (1)(8)
Electronics, Physics, Telecommunications
Kris Hertoghe (1)(7)
Electronics, Mechanics, Physics
Thierry Dubost (1)(2)(6)
Chemistry, Biochemistry, Pharmaceuticals
Liesbet Paemen, Ph.D. (1)
Life Sciences, Biotechnology, Biomedics
Michel Marchau (1)(7)(9)
Electronics, Physics, Telecommunications
Wim Van Steenlandt (7)
Mechanics, Electromechanics, Fibres
Ivo De Baere, Ph.D.
Biotechnology, Life Sciences
An De Vrieze
Semiconductor Processing, Chemistry
Davy Wauters, Ph.D.
Physics, Optics
Birgit Verbeure, Ph.D.
Pharmaceuticals, Chemistry, Biochemistry
Christophe Ego, Ph.D.
Chemistry
Hannes Iserentant, Ph.D.
Life Sciences, Biology, Biomedical Sciences
consultant
Peter N. Cutforth, MA Eng (Cambridge) (1)(2)(3)(4)
Telecommunications, Software, Electronics



Klein Dalenstraat 42A
3020 Winksele
Belgium

tel +32-16-480562
fax +32-16-480528
email 106113.713@compuserve.com
www.birdgoen.com

European Patent (1) and Trademark (2) Attorney
Registered British Patent (3) and Trademark (4) Agent
Deutscher Patentassessor (5)
French Patent and Trademark Attorney (6)
Belgian Patent Attorney (7)
Ingénieur en Propriété Intellectuelle (CEIPI) (8)
Luxemburg Patent Attorney (9)

EUROPEAN PATENT OFFICE
International Preliminary Examining Authority
Mr. D. Klein (Examiner)
Erhardtstrasse 27
D-80469 München
Duitsland

✓ FAX 00 49 89 2399 4465 + confirmation

Winksele, April 6, 2006

Re: International patent application PCT/BE2005/000032
Filing date: 4 March 2005
Applicant: K.U.Leuven Research & Development
Title: "Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production"
Our ref: K3234-PCT/go/av

Dear Mr. Klein,


As requested during our telephone call of April 3, 2006 for which we thank you, please find enclosed without prejudice handwritten amended claim pages 13 and 14. As two claims were numbered "7" we have corrected the numbering and adapted the reference to preceding claims accordingly. The content of the claims has not been changed.

Very truly yours,


Ariane Bird

encl.: amended claims, page 13 and 14 (in triplicate)


- ⁸
1. The use of a compound according to any of the claims 1 to 4, for the manufacture of a medicament for the prevention or treatment of a viral infection in a mammal.
- ⁹
- 5 ⁸ 2. The use according to claim ⁷, wherein said viral infection is an infection by the Human Immunodeficiency Virus (HIV).
- ¹⁰
- 10 3. A pharmaceutical composition comprising a compound according to any of the claims 1 to 4 as an active ingredient in admixture with at least a pharmaceutically acceptable carrier.
- ¹¹
10. A pharmaceutical composition according to claim ⁹, further comprising an antiviral agent.
- ¹²
- 15 11. A method of treatment or prevention of a viral infection in a mammal, comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound according to any of claims 1 to 4.
- ¹³
- 20 12. A compound represented by one of the following general formulae (XXVIII) to (XXX):



(XXVIII).



(XXIX), and



(XXX),

5 wherein:

- U is an acyl group,
- V is a silyl group, and
- the snake-like symbol means any stereochemical arrangement of the respective bond.

10

14 13. Use of a compound according to claim *12* as an intermediate for making a compound according to any of claims 1 to 4.

13